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Abstract
Background: Nivolumab is administered in a weight-based or fixed-flat dosing regimen. For patients with non-small
cell lung cancer (NSCLC), a potential exposure-response relationship has recently been reported and may argue against
the current dosing strategies. The primary objectives were to determine nivolumab pharmacokinetics (PK) and to
assess the relationship between drug clearance and clinical outcome in NSCLC, melanoma, and renal cell cancer (RCC).
Methods: In this prospective observational cohort study, individual estimates of nivolumab clearance and the impact
of baseline covariates were determined using a population-PK model. Clearance was related to best overall response
(RECISTv1.1), and stratified by tumor type.
Results: Two-hundred-twenty-one patients with metastatic cancer receiving nivolumab-monotherapy were included
of whom 1,715 plasma samples were analyzed. Three baseline parameters had a significant effect on drug clearance
and were internally validated in the population-PK model: gender, BSA, and serum albumin. Women had 22% lower
clearance compared to men, while the threshold of BSA and albumin that led to > 20% increase of clearance was >
2.2m2 and < 37.5 g/L, respectively. For NSCLC, drug clearance was 42% higher in patients with progressive disease
(mean: 0.24; 95% CI: 0.22–0.27 L/day) compared to patients with partial/complete response (mean: 0.17; 95% CI: 0.15–
0.19 L/day). A similar trend was observed in RCC, however, no clearance-response relationship was observed in
melanoma.
Conclusions: Based on the first real-world population-PK model of nivolumab, covariate analysis revealed a significant
effect of gender, BSA, and albumin on nivolumab clearance. A clearance-response relationship was observed in NSCLC,
with a non-significant trend in RCC, but not in melanoma. Individual pharmacology of nivolumab in NSCLC appears
important and should be prospectively studied.
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Background
Nivolumab is a human immunoglobulin G4 (IgG4)
monoclonal antibody (MoAb) that inhibits the inter-
action between the co-inhibitory immune receptor pro-
grammed death-1 (PD-1) and its ligands, PD-L1 and
PD-L2. Nivolumab monotherapy has been approved for
several indications, including advanced and metastatic
melanoma [1], advanced clear-cell renal cell cancer
(RCC), and metastatic non-small-cell lung cancer
(NSCLC) [2, 3]. IgG4 MoAbs, such as nivolumab, are
characterized by a relatively high molecular mass, lead-
ing to a slow distribution in tissues [4]. The elimination
of nivolumab is very much alike endogenous immuno-
globulins with a half-life of approximately 27 days [5]
and a steady-state at 12 weeks.
In current clinical practice, nivolumab is administered
in different schedules including 3mg/kg Q2W, 240mg flat
dosing Q2W, and 480mg flat dosing Q4W. The dosing of
3mg/kg Q2W --approved by the Food and Drug Admin-
istration (FDA) in 2014 -- was based on dose-finding
phase I/II studies, showing tolerability for the wide range
of 0.1 to 10mg/kg, and showing activity at 0.1 mg/kg
Q2W and higher [6]. However, approval of nivolumab flat
dosing (in March 2018), however, was solely based on in
silico studies: selected flat doses were based on equiva-
lence with initial dosing at median body weight of 80 kg.
Population pharmacokinetic (PPK) modeling of data from
approximately 100 clinical trials was used to simulate
nivolumab concentrations and to compare flat dosing reg-
imens (240mg Q2W, 480mg Q4W) with 3mg/kg Q2W
dosing [7, 8]. It is noteworthy that a previous model-based
PPK analysis resulted in significant but not clinically rele-
vant covariate effects, of which gender and body weight
were the most important [9].
Few studies have assessed dose-response (D-R) and ex-
posure-response (E-R) relationships of nivolumab. In a
quantitative analysis [10] of a phase 1b dose-escalation
study in 129 patients with NSCLC [6], a positive D-R re-
lationship was found at 3 or 10 mg/kg versus 1 mg/kg.
In addition, trough concentrations at steady state were
correlated with objective response (OR) at 0.1 to 3mg/
kg in another cohort of patients with NSCLC [10]. A D-
R relationship could not be demonstrated in patients
with melanoma (n = 107) nor RCC (n = 34) at this dose
range, but was only observed at 0.1 up to 1 mg/kg. In
221 melanoma patients treated in phase 1b [6] and 3
studies [11], absence of an E-R relationship was con-
firmed utilizing PPK modeling by relating the time-aver-
aged nivolumab concentration to OR [12].
In a recent real-world study performed by our group,
a steep positive E-R relationship of nivolumab was found
for NSCLC (n = 76). Here, patients with a partial re-
sponse (PR) had significant higher mean trough levels
during therapy than patients with progressive disease
(PD), and high exposure correlated significantly with
better overall survival (OS) [13].
The present study addresses the PK of nivolumab
in a real-world setting. The main objectives were 1)
to define patient parameters influencing nivolumab
pharmacokinetics and 2) to describe the relationship
of systemic nivolumab clearance with objective re-
sponse in patients with NSCLC, melanoma, and RCC.
Secondary objectives include an exploratory analysis
in regard to immune-related adverse events (irAEs),
progression-free survival (PFS), and OS.
Methods
Patients and study design
Patients with advanced cancer who were treated with
nivolumab between 20th April 2016 and 30th October
2018 at the Erasmus MC Cancer Institute (Rotterdam,
The Netherlands) and the Amphia Hospital (Breda, The
Netherlands) were included prospectively in this study
(Dutch Trial Register number NTR7015/ NL6828),
allowing for serial blood sampling during standard of
care nivolumab treatment. The study was approved by
the independent ethics committee (MEC 16–011) and
all patients provided written informed consent. Blood
samples were drawn prior to every 2-weekly nivolumab
to measure trough concentrations. For those patients
who gave extensive informed consent, intensive sam-
pling was performed between the first and second
administration of nivolumab. Patient characteristics and
clinical data were prospectively collected.
Pharmacokinetic measurements
For all patients (n = 221), nivolumab trough concen-
trations were determined for a selection of serum
samples until end of treatment. Nivolumab serum
concentrations were determined by an in-house devel-
oped and validated enzyme-linked immune sorbent
assay (ELISA, as described previously [14]. Serum
samples were selected to determine trough concentra-
tions prior to each administration for the first 12
weeks, thereafter at evenly 12-weekly intervals until
the end of treatment. For some patients (n = 3), inten-
sive sampling allowed to determine nivolumab con-
centrations at 2 h, 2 days, and 1 week after the first
administration in order to estimate a best-fit compart-
mental model.
Data collection
The following baseline patient parameters were col-
lected: gender, race, tumor type, performance status, age,
body weight, body surface area (BSA), total volumetric
tumor burden, serum creatinine, renal function, total
serum protein, serum albumin, lactate dehydrogenase
(LD) and leucocyte count. Performance status was
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determined according to Eastern Cooperative Oncology
Group [15]. For NSCLC patients, weight loss was re-
corded and defined as a percentage of 2.5 or higher [16]
during a period of 3 months prior to the first adminis-
tration of nivolumab. BSA was calculated by the Mostel-
ler equation [17]. Renal function was estimated using
the Chronic Kidney Disease Epidemiology Collaboration
(CKD-EPI) formula [18].
For a subgroup of NSCLC patients (n = 30), total volu-
metric tumor burden at baseline was assessed by a thor-
acic radiologist (A.O.) in a blinded manner using
IntelliSpace Portal version 8 (Philips Medical Systems
Nederland B.V., The Netherlands). Only primary tumor
lesions with a long axis > 10mm, lymph nodes with a
short axis > 15 mm and metastatic lesions with a long
axis > 10mm were included. Total volumetric tumor
burden was not assessed if the primary tumor was not
identifiable or its boundaries could not be defined, e.g.
due to surrounding atelectasis or radiation effects.
Best overall response (BOR) was assessed according to
Response Evaluation Criteria in Solid Tumors version
1.1 (RECIST v1.1, [19]). A minimum duration of 90 days
for stable disease (SD) was required. Confirmation of PR
or complete response (CR) was not required. PFS was
defined as the time from the first administration of
nivolumab until PD or death due to any cause, which-
ever occurred first. OS was defined as the time from the
first administration of nivolumab until death due to any
cause. IrAEs were registered from start of treatment
until end of follow-up according to National Cancer
Institute Common Terminology Criteria for Adverse
Events version 4.03 (NCI-CTCAE v4.03). Data cut-off
for these analyses was set at 1st of January 2019.
Pharmacokinetic modeling
To determine patient parameters influencing nivolu-
mab PK (primary objective 1), nonlinear mixed effect
modeling software, NONMEM (version 7.4; ICON,
Development Solutions, MD) was used to analyze the
PK data. The first-order conditional estimation
method with interaction was used for parameter esti-
mation. Pirana software version 2.9.7 (Pirana, www.
pirana-software.com) was used as a modeling environ-
ment, and data were further handled in the latest R
desktop version 1.1.453 (R-project, www.rproject.org).
A two-compartment PPK model was developed to best
fit the nivolumab pharmacokinetics with individual esti-
mates of systemic drug clearance (schematically shown
in Additional file 1: Figure S1). Two-compartment PPK
models have previously been described to best fit
pharmacokinetics of monoclonal antibodies in blood
[20]. Since we had only trough PK levels available,
modelling of nivolumab distribution was challenging.
Hence, we assumed that the central volume (V1) equals
the peripheral volume of distribution (V2) as previously
described for nivolumab [21].
Between-subject variability (BSV) was tested for clear-
ance and distribution volume. The inclusion of BSV was
evaluated according to the change of objective function
value (OFV, P < 0.05) and shrinkage. A shrinkage value
below 25% was considered acceptable [22].
BSV was modelled according to Eq. 1:
Pi ¼ P∙ exp ηi
  ð1Þ
where Pi represents the parameter estimate for each in-
dividual patient (i), P represents the typical population
parameter estimate and ηi represents BSV distributed ac-
cording to N (0, ω2).
Residual errors were described by a proportional error
model (Eq. 2):
Cobs;ij ¼ Cpred;ij  1þ εp;ij
  ð2Þ
where Cobs,ij and Cpred,ij represent the observed and pre-
dicted concentration for the (i) th subject and the (j) th
measurement, respectively. εp,ij represents the propor-
tional error distributed according to N (0,σ2).
Covariates were added to the PPK model (initial model
Mi) to obtain a final model (final model Mf). Potential
covariates were selected based on clinical plausibility
and tested by a stepwise approach with forward inclu-
sion (threshold p < 0.01) and backward elimination
(threshold p < 0.005, [23–25]). The covariates were
tested on clearance (CL) by multiplying a typical clear-
ance value (CLTV) with a factor for categorical (Factorcat)
and continuous (Factorcon) covariates (Eq. 3).
CL ¼ CLTV  Factorcat  Factorcon ð3Þ
Categorical covariates were scored as ‘0’ or ‘1’. Equation 4
was applied for patients who scored ‘1’ in which θx repre-
sents the covariate effect size estimate. Continuous vari-
ables were tested with the PK model using Eq. 5 where cov
represents the covariate measure, covmedian the population
median of the covariate, and θy the covariate effect
measure.
Factorcat ¼ 1þ θx ð4Þ
Factorcon ¼ covcovmedian
 θy
ð5Þ
Data analysis
Descriptive statistics included frequency and the median
with range and inter-quartile range (IQR) of covariates.
To analyze the relationship of systemic nivolumab clear-
ance, which is inversely proportional to drug exposure,
with treatment outcome (primary objective 2), patients
were stratified by tumor type (NSCLC, melanoma, and
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RCC) and ranked according to BOR. To avoid potential
confounding from covariates that may correlate with
response, the initial model Mi was used to compare indi-
vidual drug clearance estimates between different BOR
groups (PD, SD, PR/CR). Equal variances among groups
were assessed with Levene’s test, normal distribution
was assessed using the skewness and kurtosis. Compari-
son of individual drug clearance was assessed for the
three BOR groups by ANOVA and post-hoc independ-
ent samples t-tests.
To investigate the relationship of systemic nivolumab
clearance with toxicity, patients were stratified by tumor
type, grouped based on the occurrence of grade 0–2 or
grade > 3 irAEs, and analyzed by independent samples t-
test. To relate systemic nivolumab clearance to PFS and
OS, NSCLC patients were grouped into quartiles: pa-
tients with low clearance (Q1) were compared with pa-
tients with high clearance (Q4) by the Kaplan-Meier
approach. The relative risk of death or death/progression
was assessed by the Cox proportional hazards model.
Additional patient characteristics were included grouped
by clearance quartile (Q1-Q4). A two-sided p-value < 0.05
was considered significant.
Post-processing of NONMEM generated data and
statistical analysis was conducted with R and IBM
SPSS Statistics version 24.0.0.1 (Chicago, IL).
Results
A total of 221 nivolumab-treated cancer patients were
included in the PPK model (Mi and Mf): NSCLC
(71.4%), melanoma (21.7%), RCC (6.3%), and one
mesothelioma patient. The patient characteristics are
shown in Table 1. One patient received ipilimumab after
initial treatment with nivolumab monotherapy, and was
excluded from clearance-response, clearance-survival
and clearance-toxicity analysis. Dosing was based on
body weight (3 mg/kg Q2W), with an average dose of
240 mg per administration (IQR: 200–280 mg). The aver-
age number of nivolumab cycles administered per pa-
tient was 12. The overall median follow up time (from
first administration of nivolumab to censoring) was 338
days (IQR: 145–487 days). A total of 1,715 measure-
ments were available for PK analysis (average of 8 mea-
surements per patient). Examples of nivolumab
measurements and administrations over time from two
patients, one with and one without dose delays, are
shown in Fig. 1.
Gender, BSA and albumin influence nivolumab
pharmacokinetics
Continuous and categorical clinical covariates were incor-
porated in the final two-compartment model by forward
inclusion and backward elimination (Additional file 1:
Table S1), resulting in four covariates reaching the
significance threshold, namely: gender, BSA, albumin,
and body weight. BSA had a higher impact on nivolu-
mab pharmacokinetics than weight; the latter being
rejected by the backward elimination step. The par-
ameter estimates according to the Mf are shown in
Table 2 including the results of internal validation.
The NONMEM model can be found Additional file 1:
Appendix 1. Inter-individual variance was reduced
from 37% (as indicated by Mi) to 30.7% by incorpor-
ating these three covariates. Women had 22% lower
clearance than men, as evidenced by a mean clear-
ance of 0.185 and 0.237 L/day, respectively. The
thresholds of BSA and baseline serum albumin that
led to an estimated > 20% increase of systemic nivolu-
mab clearance were > 2.2 m2 (BSA) and < 37.5 g/L (al-
bumin), respectively (Fig. 2).
Correlation between drug clearance and clinical outcome
Clinical outcome and occurrence of toxicity are shown
in Additional file 1: Table S2. The initial model (Mi) was
used to investigate the relationship between individual
clearance of nivolumab and clinical response or toxicity
in NSCLC, melanoma, and RCC (Fig. 3b-d). A negative
clearance-response relationship was found in patients
with NSCLC (p < 0.001), as a significantly higher
clearance of 41.8% was observed in patients with PD
(mean: 0.244; 95% CI: 0.223–0.265 L/day) compared to
patients with PR/CR (0.172; 0.152–0.192). Patients with
SD were identified as an intermediate group (0.211;
0.193–0.228). A non-significant trend similarly to NSCLC
was observed in RCC (p = 0.054). Of note, no clearance-
response relationship was observed in melanoma (p =
0.987). A clearance-irAE relationship was not found
for NSCLC, melanoma, or RCC (respectively p = 0.28,
p = 0.84 and p = 0.92; Additional file 1: Figure S2B-D),
nor for all three tumor types pooled together (p =
0.31; Additional file 1: Figure S2A).
There was no significant difference in drug clearance
between tumor types (p = 0.47; Fig. 3a), corresponding
with above-mentioned PPK modeling where tumor type
as a categorical covariate did not reach the significance
threshold. Notably, when patients with NSCLC were
grouped by clearance, the lowest quartile of clearance
was significantly associated with better PFS (HR 0.32;
95% CI: 0.18–0.57, p < 0.001) and OS (HR: 0.25; 95% CI:
0.12–0.51, p < 0.001) compared to patients with the
highest quartile of clearance (Fig. 4a-b). Additionally, the
patient characteristics grouped by quartile of clearance
are shown in Additional file 1: Table S3.
Discussion
In the current study, we showed that gender, baseline
BSA, and serum albumin had a significant effect on the
systemic clearance of nivolumab in the two compartment
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PPK model. These three covariates partially explained the
high inter-individual variance (~ 37%) of drug clearance.
Secondly, we have demonstrated the relationship between
nivolumab pharmacokinetics and radiological response to
therapy. By stratifying tumor types, the negative clearance-
response relationship was highly significant in NSCLC, and
a non-significant trend was seen in RCC. The clearance-re-
sponse relationship could not be confirmed in melanoma.
Our developed PPK model was comparable to previ-
ously described models for different MoAbs and
nivolumab. In a model-based meta-analysis for four dif-
ferent MoAbs a robust fit was obtained using a two-
Table 1 Patient characteristics
Demographic Covariates Categorical n (%)
Tumor Type
NSCLC all types 158 (71.5)
Non-Squamous 96
Squamous 42
Unknown NSCLC type 20
Melanoma 48 (21.7)
RCC 14 (6.3)
Mesothelioma 1 (0.5)
Treatment
Nivolumab monotherapy (3 mg/kg Q2W) 221 (100)
Gender
Male 138 (62.4)
Female 83 (37.6)
Race
Caucasian 195 (88.2)
Other 5 (2.3)
Unknown 21 (9.5)
WHO Performance Status
0 63 (28.5)
1 103 (46.6)
2 4 (1.8)
Unknown 51 (23.1)
Weight loss prior to start therapy (only in NSCLC)
Yes 36 (16.3)
No 81 (36.7)
Unknown 104 (47.1)
Demographic and Laboratory Covariates Continuous Median (IQR) n (%)
Age (yr) 65 (59–71) 221 (100)
Body Weight (kg) 78.5 (70–88) 220 (99.5)
Body Surface Area (m2) 1.95 (1.81–2.09) 205 (93)
Tumor Burden 3D (cm3; only in NSCLC) 18.6 (66–98) 25 (11)
Creatinine (μmol/L) 81 (66–98) 203 (92)
CKD (mL/min) 81 (62–90) 203 (92)
Total Protein (g/L) 73 (69–90) 163 (74)
Albumin (g/L) 42 (42–45) 174 (79)
LD (U/L) 215 (183–275) 196 (89)
Leucocytes (109 cells/L) 7.7 (6.3–10.2) 203 (92)
Baseline covariates of patients
Abbreviations: n number of patients, IQR inter-quartile range, CKD CKD-EPI renal clearance, LD lactate dehydrogenase
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compartment model with estimates for systemic clear-
ance and volume of distribution of 0.200 L/day and 3.6
L, respectively, and with a 31% inter-subject variability
of clearance [20]. This was similar to recently published
parameter estimates of a nivolumab-based two-compart-
ment model described by Bajaj and colleagues (clearance
0.226 L/day; compartmental volume 3.6; 35% inter-sub-
ject variability of clearance) [9]. Although the time-vary-
ing pharmacokinetics as described by Liu et al. [21]
could not be confirmed in our analysis, our time-station-
ary PPK model worked with sufficient accuracy. Import-
ant to note is that we observed that trough levels
Fig. 1 Patient examples. Example of two subjects (2010: NSCLC, 1015: melanoma patient) showing concentrations of nivolumab (mg/L) versus
time (weeks), with received administrations of nivolumab being marked as open triangles. Single measurements are represented by closed circles.
a Note that patient 2010 experienced several dose delays followed by a decrease of nivolumab concentrations that was in line with the
approximate half-life time of 25 days, whereas b patient 2015 has had no dose delays and demonstrated a time to steady state concentrations of
approximately 20 weeks
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reached steady state concentrations and remained stable
over time in individual patients (as illustrated by Fig. 1b).
Estimated systemic drug clearance according to the
PPK model, which is inversely proportional to expos-
ure, was utilized in this study to correlate clearance
with response, survival, and occurrence of irAEs. It is
important to realize that correlating systemic clear-
ance to treatment outcome using a PPK model may
potentially be influenced by those incorporated base-
line covariates that are related to the efficacy of
immunotherapy. To avoid such confounding, we uti-
lized the initial model to demonstrate the relationship
of systemic clearance with clinical outcome, which
was further grouped by tumor type. Two patients
were excluded from these analyses: a patient with
mesothelioma and a patient who was treated with
concomitant ipilimumab from the second cycle of
nivolumab, at which point he was censored from the
analyses.
The differential clearance-response relationship of
nivolumab in NSCLC compared to melanoma remains
to be elucidated. This may be explained by different
tumor intrinsic as well as extrinsic factors, such as
tumor immunogenicity and patient immunity (e.g.
microbiota, environmental factors) respectively. In
addition, positive D-R relationships were found for
NSCLC at doses from 0.1 to 3 mg/kg Q2W [10], whereas
for melanoma this was only observed at doses from 0.1
to 1 mg/kg Q2W [10]. In this respect it is noteworthy
that the ORR of nivolumab in metastatic melanoma is
superior compared to metastatic NSCLC [1–3]. In our
study, patients with melanoma demonstrated better per-
formance than patients with NSCLC before initiation of
nivolumab monotherapy (WHO performance score of 0:
76 and 23%, respectively). Taken together, we cannot
exclude that nivolumab may be effective at lower doses
for patients with melanoma than for NSCLC, and that
patients with NSCLC may be more sensitive for changes
in exposure than patients with melanoma. Consequently,
nivolumab dosing based on weighted parameters may be
relevant to optimize efficacy, particularly for NSCLC
patients.
Whether the inverse clearance-response relation for
nivolumab in NSCLC indicate a true causal effect on
clinical outcome remains to be clarified. The issue was
discussed by Badawi in a comment on our previous
work showing a positive E-R relationship of nivolumab
for NSCLC [13, 26]. Of note, an absent E-R relationship
but a strong negative clearance-OS association has been
described for pembrolizumab, another PD-1 blocking
monoclonal antibody, in solid tumors [27]. The efficacy
of pembrolizumab seemed to be independent of absolute
doses from 2 to 10mg/kg Q2W or flat dose 200 mg
Q3W. Turner and colleagues argued that this clearance-
OS relationship was confounded by the cachectic state
of patients, which caused more rapid protein (and thus
antibody) turnover and worse survival [27]. Given the
circular reasoning in their study design, however, this
hypothesis may not have been supported by appropriate
evidence [28]. Although we did not find a covariate ef-
fect of prior weight loss or the performance score on the
PPK model, serum albumin was inversely correlated with
nivolumab clearance. Albumin may be considered as a
surrogate marker for protein clearance, coinciding with
clearance of endogenous immunoglobulins and nivolu-
mab. This may provide supporting evidence to the
Table 2 Parameter estimates
Parameters Units Estimate RSE (%) Bootstrap estimate Bootstrap
95% CI
Population parameters
Clearance (CL) L/day 0.211 3.5 0.211 0.196 to 0.226
Central volume of distribution (V1) L 3.46 5.8 3.46 3.09 to 3.83
Peripheral volume of distribution (V2) L 3.46 5.8 3.46 3.09 to 3.84
Inter-compartmental clearance (Q) L/day 0.48 < 0.1 0.48 0.48 to 0.48
Covariate effects
Female gender on CL – −0.17 29.1 −0.17 −0.27 to −0.06
BSA effect on CL – 0.97 24.1 0.96 0.48 to 1.45
Albumin effect on CL – −1.34 19.8 −1.33 −1.83 to − 0.86
Between-subject variability
Clearance (CL) CV% 30.7 9 30.3 24.8 to 35.6
Residual unexplained variability
Proportional error CV% 31.8 8 31.8 29.1 to 34.2
Population parameters, covariate effects and between-subject variability according to the final population pharmacokinetic model (Mf). Abbreviations: CL
clearance, RSE relative standard error, CV% percentage coefficient of variation, CI confidence interval. The shrinkage of the between-subject variability of clearance
and the proportional error was 9.2 and 4%, respectively
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hypothesis that the exposure-response (or inverse clear-
ance-response) relationship is affected by the metabolic
state of patients, although we cannot rule out the possi-
bility of a true causal relationship.
The elimination and recycling mechanisms of nivolu-
mab is expected to exhibit similarities to those of en-
dogenous immunoglobulins with a central role for the
neonatal Fc receptor (FcRn) [29]. The FcRn is being
widely expressed in human tissue (www.proteinatlas.org),
particularly in myeloid cells, and reported to play a key
role in the metabolism of albumin in blood [30]. Interest-
ingly, myeloid cells have emerged as major regulators of
cancer immune response by presenting tumor antigens to
T cells and controlling the activity of cytotoxic cells, where
myeloid-derived suppressor cells (MDSCs) suppress T cell
responses and are implicated in tumor metastasis [31, 32].
In fact, MDSCs were negatively associated with response
to treatment and survival in NSCLC [33, 34]. Monocytic
myeloid cells in peripheral blood prior to anti-PD-1 nivo-
lumab and pembrolizumab are associated with inferior
Fig. 2 Parameter effect on clearance: a Estimated nivolumab clearance (L/day) as a function of a baseline serum albumin (g/L) and b body
surface area (BSA; m2). Single measurements are represented by open circles. The red line predicts clearance according to the final PPK model
(Mf). The horizontal dotted lines marks the 20% increase of clearance, taking the mean clearance as reference (solid line). The vertical dotted line
mark the threshold where nivolumab clearance is expected to be increased by > 20%
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Fig. 3 Clearance-response analysis: a Nivolumab clearance (L/day) of a all patients receiving nivolumab monotherapy grouped by best overall
response (BOR), and stratified by b NSCLC, c melanoma, and d RCC. Single measurements are represented by open circles. Bars indicate the 95%
confidence interval of the mean. Abbreviations: progressive disease (PD), stable disease (SD) and partial response/ complete response (PR/CR).
P-values indicated by *** < 0.001 (post-hoc independent samples t-test)
Fig. 4 Kaplan-Meier curves: a progression-free survival (PFS) and b overall survival (OS) of NSCLC patients receiving nivolumab monotherapy
stratified by clearance into 4 quartiles of clearance displayed by Kaplan-Meier methodology: Q1 [first quartile (blue); lowest clearance] - Q4 [fourth
quartile (red); highest clearance]
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PFS and OS [35]. We expect that by further exploring the
interaction between the peripheral immune system, e.g.
FcRn in the myeloid lineage, and nivolumab pharmacokin-
etics, understanding of immune checkpoint inhibitor
treatment could be significantly enhanced.
Conclusions
In oncology, pharmacokinetic modeling is widely used to
optimize drug dosing. For immune checkpoint inhibitors,
approved flat dosing regimens for nivolumab have been
solely based on simulations from dose-finding clinical trials.
In this prospective real-life patient cohort study, we ob-
served an effect of gender, body surface area, and baseline
serum albumin on systemic drug clearance, thereby provid-
ing understanding of the high inter-individual variance of
clearance. We demonstrate a strong inverse correlation of
drug clearance and response in NSCLC, and a similar trend
in RCC, but a clearance-response relationship was not ob-
served in melanoma. Considering the recent approval of
nivolumab fixed dosing regimens --which was solely based
on simulating PK data from clinical studies-- this real-world
study suggests that dosing regimens based on patient pa-
rameters may be considered to improve efficacy, particu-
larly in NSCLC, and should be prospectively studied.
Dutch Trial Registry NL6828. Registered 5 April 2016,
https://www.trialregister.nl/trial/6828.
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